Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 2.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 474,257 shares of the company’s stock after acquiring an additional 11,390 shares during the period. Charles Schwab Investment Management Inc. owned about 0.23% of Taysha Gene Therapies worth $820,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock valued at $7,163,000 after purchasing an additional 682,273 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Taysha Gene Therapies in the third quarter valued at $931,000. Barclays PLC raised its holdings in shares of Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after buying an additional 193,046 shares during the period. State Street Corp raised its holdings in shares of Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after buying an additional 150,647 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Taysha Gene Therapies by 1.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock valued at $6,033,000 after acquiring an additional 37,844 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Chardan Capital reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Stock Up 2.7 %

Shares of NASDAQ:TSHA opened at $1.93 on Monday. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The firm’s 50 day moving average price is $1.65 and its 200 day moving average price is $1.91. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market cap of $395.65 million, a price-to-earnings ratio of 3.06 and a beta of 0.91.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. As a group, equities research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.